董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sangita Shah | 女 | Director | 58 | 10.00万美元 | 未持股 | 2024-01-02 |
| Sharon Hrynkow | 女 | Director | 64 | 8.00万美元 | 未持股 | 2024-01-02 |
| James Ziglar | 男 | Director | 79 | 8.00万美元 | 未持股 | 2024-01-02 |
| Terence Wise | 男 | Chief Executive Officer and Chairman of the Board | 76 | 33.70万美元 | 未持股 | 2024-01-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Wild | 男 | Chief Operating Officer of IPS | 53 | 35.14万美元 | 未持股 | 2024-01-02 |
| Paul Severino | -- | President of IPS | 65 | 37.03万美元 | 未持股 | 2024-01-02 |
| Tom KraMer | 男 | Chief Executive Officer of Kablooe, Inc. | 59 | 26.97万美元 | 未持股 | 2024-01-02 |
| Kathleen Weisberg | 女 | Chief Financial Officer | 53 | 6.45万美元 | 未持股 | 2024-01-02 |
| Terence Wise | 男 | Chief Executive Officer and Chairman of the Board | 76 | 33.70万美元 | 未持股 | 2024-01-02 |
董事简历
中英对照 | 中文 | 英文- Sangita Shah
-
Sangita Shah，目前她除了担任Bilby PLC非执行董事长和Swindon Town Football Club的董事，她还是Odyssean Enterprises Limite（一个私人咨询和投资公司）d的所有人以及董事。她也是Global Reach Technology（一个WiF快速通道中小企业）董事会顾问和Zypha Technologies Inc的非执行董事。
Sangita Shah currently serves as director and owner of Odyssean Enterprises Limited, a private advisory and investment company, in addition to serving as non-executive chairman of Bilby PLC and non-executive chairman of RA International PLC. Ms. Shah is also a board advisor to Global Reach Technology, a Fast Track WiFi company. Ms. Shah previously worked in seed/mezzanine financing and strategic investments within the environmental and technology sectors following a number of senior roles held at KPMG and Ernst & Young. - Sangita Shah，目前她除了担任Bilby PLC非执行董事长和Swindon Town Football Club的董事，她还是Odyssean Enterprises Limite（一个私人咨询和投资公司）d的所有人以及董事。她也是Global Reach Technology（一个WiF快速通道中小企业）董事会顾问和Zypha Technologies Inc的非执行董事。
- Sangita Shah currently serves as director and owner of Odyssean Enterprises Limited, a private advisory and investment company, in addition to serving as non-executive chairman of Bilby PLC and non-executive chairman of RA International PLC. Ms. Shah is also a board advisor to Global Reach Technology, a Fast Track WiFi company. Ms. Shah previously worked in seed/mezzanine financing and strategic investments within the environmental and technology sectors following a number of senior roles held at KPMG and Ernst & Young.
- Sharon Hrynkow
-
Sharon Hrynkow，从2012年10月至2015年11月，她曾是the Global Virus Network（顶尖的医学病毒学家联盟，进行茎病毒性疾病的传播研究）就任总裁。她也是Global Health Consulting, LLC的创始人和合伙人和CTD医疗事务的高级副总裁。从2010年到2012年，她是the Secretary of State’s Office of Science and Technology的秘书的顾问，资深科学家和海洋、环境和科学助理部长的高级顾问。从2000年到2012年，她担任the National Institute of Health高级主管职务，主要担任the John E. Fogarty International Center副主任。她当选为Council on Foreign Relations and the American Association for the Advancement of Science成员。
Sharon Hrynkow,is Founder and Managing Partner of Global Health Consulting, LLC, an advisory group assisting clients on federal funding opportunities and strategies to grow life science companies. Prior roles include Chief Scientific Officer and Senior VP for Medical Affairs at Cyclo Therapeutics (Nasdaq: CYTH) where she launched and led its drug development programs (2015 to 2022); a range of senior executive positions in global health and global science at the National Institutes of Health and Department of State (1992 – 2012); and, as inaugural president of the Global Virus Network, a non-profit group working to combat the spread of viral disease (2012 – 2015). Dr. Hrynkow is an elected member of the Council on Foreign Relations and an elected Fellow of the American Association for the Advancement of Science. She advises a range of non-profit organizations on science and health matters, including the National Academies of Sciences, Engineering and Medicine, and has served as an appointee to the President's Council of Advisors on Science and Technology. - Sharon Hrynkow，从2012年10月至2015年11月，她曾是the Global Virus Network（顶尖的医学病毒学家联盟，进行茎病毒性疾病的传播研究）就任总裁。她也是Global Health Consulting, LLC的创始人和合伙人和CTD医疗事务的高级副总裁。从2010年到2012年，她是the Secretary of State’s Office of Science and Technology的秘书的顾问，资深科学家和海洋、环境和科学助理部长的高级顾问。从2000年到2012年，她担任the National Institute of Health高级主管职务，主要担任the John E. Fogarty International Center副主任。她当选为Council on Foreign Relations and the American Association for the Advancement of Science成员。
- Sharon Hrynkow,is Founder and Managing Partner of Global Health Consulting, LLC, an advisory group assisting clients on federal funding opportunities and strategies to grow life science companies. Prior roles include Chief Scientific Officer and Senior VP for Medical Affairs at Cyclo Therapeutics (Nasdaq: CYTH) where she launched and led its drug development programs (2015 to 2022); a range of senior executive positions in global health and global science at the National Institutes of Health and Department of State (1992 – 2012); and, as inaugural president of the Global Virus Network, a non-profit group working to combat the spread of viral disease (2012 – 2015). Dr. Hrynkow is an elected member of the Council on Foreign Relations and an elected Fellow of the American Association for the Advancement of Science. She advises a range of non-profit organizations on science and health matters, including the National Academies of Sciences, Engineering and Medicine, and has served as an appointee to the President's Council of Advisors on Science and Technology.
- James Ziglar
-
James Ziglar在法律、金融、管理和公共政策方面有超过50年的经验。自2009年以来，Ziglar先生一直担任Van Ness Feldman LLP律师事务所的高级法律顾问，就广泛的业务和公共政策问题为客户提供建议。Ziglar从2005年到2008年担任Cross Match Technologies，Inc.（生物识别技术领先供应商）总裁和首席执行官。Ziglar先生拥有18年的投资银行经验，在2005年加入Cross Match Technologies之前，Ziglar先生是纽约UBS Financial Services，Inc.的董事总经理兼首席业务策略师。Ziglar先生任职于Integrated Biometrics，Inc.的董事会，并在美国政府有着丰富的经验，曾担任最高法院法官Harry Blackmun的法律书记员，内政部助理部长，移民和归化局专员，作为美国参议院武器部门的中士。
James Ziglar has over 50 years of experience in law, finance, management, and public policy. Since 2009, Mr. Ziglar has served as Senior Counsel to the law firm of Van Ness Feldman LLP, advising clients on a broad range of business and public policy issues. From 2005 until 2008, Mr. Ziglar was the President and Chief Executive Officer of Cross Match Technologies, Inc., a leading provider of biometric technologies. Mr. Ziglar has 18 years of experience in investment banking and before joining Cross Match Technologies in 2005, Mr. Ziglar was a Managing Director and Chief Business Strategist at UBS Financial Services, Inc. in New York. Mr. Ziglar serves on the Board of Integrated Biometrics, Inc., and has had extensive experience in the U.S. government, having served as a Law Clerk to Supreme Court Justice Harry Blackmun, as Assistant Secretary of the Interior, as Commissioner of the Immigration and Naturalization Service, and as Sergeant at Arms of the U.S. Senate. - James Ziglar在法律、金融、管理和公共政策方面有超过50年的经验。自2009年以来，Ziglar先生一直担任Van Ness Feldman LLP律师事务所的高级法律顾问，就广泛的业务和公共政策问题为客户提供建议。Ziglar从2005年到2008年担任Cross Match Technologies，Inc.（生物识别技术领先供应商）总裁和首席执行官。Ziglar先生拥有18年的投资银行经验，在2005年加入Cross Match Technologies之前，Ziglar先生是纽约UBS Financial Services，Inc.的董事总经理兼首席业务策略师。Ziglar先生任职于Integrated Biometrics，Inc.的董事会，并在美国政府有着丰富的经验，曾担任最高法院法官Harry Blackmun的法律书记员，内政部助理部长，移民和归化局专员，作为美国参议院武器部门的中士。
- James Ziglar has over 50 years of experience in law, finance, management, and public policy. Since 2009, Mr. Ziglar has served as Senior Counsel to the law firm of Van Ness Feldman LLP, advising clients on a broad range of business and public policy issues. From 2005 until 2008, Mr. Ziglar was the President and Chief Executive Officer of Cross Match Technologies, Inc., a leading provider of biometric technologies. Mr. Ziglar has 18 years of experience in investment banking and before joining Cross Match Technologies in 2005, Mr. Ziglar was a Managing Director and Chief Business Strategist at UBS Financial Services, Inc. in New York. Mr. Ziglar serves on the Board of Integrated Biometrics, Inc., and has had extensive experience in the U.S. government, having served as a Law Clerk to Supreme Court Justice Harry Blackmun, as Assistant Secretary of the Interior, as Commissioner of the Immigration and Naturalization Service, and as Sergeant at Arms of the U.S. Senate.
- Terence Wise
-
Terence Wise自2012年2月起任董事。他是Justwise集团主席，Justwise集团他于1977年创立。除了他的商业管理技能，他还为董事会带来了在亚洲市场的丰富经验。他还担任Forward China的总监。
Terence Wise serves as principal and Chairman of The Justwise Group Limited ("Justwise") which he founded in 1977. Mr. Wise also serves as a principal and owner of Forward Industries Asia-Pacific Corporation ("Forward China"), a buying and supplier agent in the Asia-Pacific region and has significant shareholdings in two furniture manufacturing plants in China. See the section titled "Related Person Transactions" below. - Terence Wise自2012年2月起任董事。他是Justwise集团主席，Justwise集团他于1977年创立。除了他的商业管理技能，他还为董事会带来了在亚洲市场的丰富经验。他还担任Forward China的总监。
- Terence Wise serves as principal and Chairman of The Justwise Group Limited ("Justwise") which he founded in 1977. Mr. Wise also serves as a principal and owner of Forward Industries Asia-Pacific Corporation ("Forward China"), a buying and supplier agent in the Asia-Pacific region and has significant shareholdings in two furniture manufacturing plants in China. See the section titled "Related Person Transactions" below.
高管简历
中英对照 | 中文 | 英文- Robert Wild
Robert Wild，2014年9月加入本公司。此前，2010年8月至2014年8月，他担任Eli Lilly & Company的肿瘤研究与药物开发首席科学官。此前，2006年1月至2010年7月，他在OSI Pharmaceuticals, Inc担任了愈益重要的多个职务，其中包括肿瘤学研究、体内药理学、分子成像及药物代谢动力学研究高级总监。加入OSI之前，他在Bristol-Myers Squibb工作了4年多；此前还曾任职于SUGEN, Inc.他在University of Minnesota获得药理学博士学位、生物化学学士学位。
Robert Wild joined us in September 2014. Prior to joining Ignyta, Dr. Wild was Chief Scientific Officer, Oncology Research, Drug Discovery at Eli Lilly & Company, a position he held from August 2010 to August 2014. Prior to Lilly, Dr. Wild held positions of increasing responsibility from January 2006 to July 2010 at OSI Pharmaceuticals, Inc., including Senior Director, Oncology Research, In Vivo Pharmacology, Molecular Imaging & Research DMPK. Before his tenure at OSI, Dr. Wild spent more than four years at Bristol-Myers Squibb, and he also previously worked at SUGEN, Inc. Dr. Wild holds both a Ph.D. in pharmacology and a B.S. in biochemistry from the University of Minnesota.- Robert Wild，2014年9月加入本公司。此前，2010年8月至2014年8月，他担任Eli Lilly & Company的肿瘤研究与药物开发首席科学官。此前，2006年1月至2010年7月，他在OSI Pharmaceuticals, Inc担任了愈益重要的多个职务，其中包括肿瘤学研究、体内药理学、分子成像及药物代谢动力学研究高级总监。加入OSI之前，他在Bristol-Myers Squibb工作了4年多；此前还曾任职于SUGEN, Inc.他在University of Minnesota获得药理学博士学位、生物化学学士学位。
- Robert Wild joined us in September 2014. Prior to joining Ignyta, Dr. Wild was Chief Scientific Officer, Oncology Research, Drug Discovery at Eli Lilly & Company, a position he held from August 2010 to August 2014. Prior to Lilly, Dr. Wild held positions of increasing responsibility from January 2006 to July 2010 at OSI Pharmaceuticals, Inc., including Senior Director, Oncology Research, In Vivo Pharmacology, Molecular Imaging & Research DMPK. Before his tenure at OSI, Dr. Wild spent more than four years at Bristol-Myers Squibb, and he also previously worked at SUGEN, Inc. Dr. Wild holds both a Ph.D. in pharmacology and a B.S. in biochemistry from the University of Minnesota.
- Paul Severino
自2008年联合创立IPS以来，Paul Severino一直担任IPS的首席运营官。
Paul Severino has served as the Chief Operating Officer of Intelligent Product Solutions, Inc. “IPS” since co-founding it in 2008.- 自2008年联合创立IPS以来，Paul Severino一直担任IPS的首席运营官。
- Paul Severino has served as the Chief Operating Officer of Intelligent Product Solutions, Inc. “IPS” since co-founding it in 2008.
- Tom KraMer
Tom Kramer自2020年公司收购Kablooe Design，Inc.的资产以来一直担任Kablooe的首席执行官。在此之前，Kramer先生自1993年Kablooe Design，Inc.成立起担任其首席执行官。
Tom KraMer has served as the Chief Executive Officer of Kablooe, Inc. since the Company's acquisition of the assets of Kablooe Design, Inc. in 2020. Prior to that, Mr. KraMer served as the Chief Executive Officer of Kablooe Design, Inc. since its formation in 1993.- Tom Kramer自2020年公司收购Kablooe Design，Inc.的资产以来一直担任Kablooe的首席执行官。在此之前，Kramer先生自1993年Kablooe Design，Inc.成立起担任其首席执行官。
- Tom KraMer has served as the Chief Executive Officer of Kablooe, Inc. since the Company's acquisition of the assets of Kablooe Design, Inc. in 2020. Prior to that, Mr. KraMer served as the Chief Executive Officer of Kablooe Design, Inc. since its formation in 1993.
- Kathleen Weisberg
Kathleen Weisberg，被任命为公司首席财务官，自2023年7月1日起生效。在被任命为首席财务官之前，Weisberg女士于2020年6月至2023年6月期间担任公司的公司控制人。2017年6月至2020年6月，Weisberg女士担任爬行动物和水族箱产品公司Jungle Bob Enterprises，Inc.的财务总监。2003年12月至2010年3月，Weisberg女士在WW International，Inc.（前身为Weight Watchers International，Inc.）担任SEC报告高级经理。1998年10月至2003年11月，Weisberg女士在移动数据捕获和传输设备制造商和供应商Symbol Technologies, Inc.担任高级审计师和公司会计经理。从1992年1月至1998年10月，Weisberg女士在安永会计师事务所担任审计员。
Kathleen Weisberg,was appointed the Company's Chief Financial Officer effective July 1, 2023. Prior to her appointment as Chief Financial Officer, Ms. Weisberg served as the Company's Corporate Controller from June 2020 to June 2023. From June 2017 to June 2020, Ms. Weisberg served as the Controller for Jungle Bob Enterprises, Inc., a reptile and aquarium product company. From December 2003 to March 2010, Ms. Weisberg served as the Senior Manager for SEC Reporting at WW International, Inc., formerly Weight Watchers International, Inc. From October 1998 to November 2003, Ms. Weisberg served as Senior Auditor and Corporate Accounting Manager for Symbol Technologies, Inc., a manufacturer and supplier of mobile data capture and delivery equipment. From January 1992 to October 1998, Ms. Weisberg was an auditor at Ernst & Young LLP.- Kathleen Weisberg，被任命为公司首席财务官，自2023年7月1日起生效。在被任命为首席财务官之前，Weisberg女士于2020年6月至2023年6月期间担任公司的公司控制人。2017年6月至2020年6月，Weisberg女士担任爬行动物和水族箱产品公司Jungle Bob Enterprises，Inc.的财务总监。2003年12月至2010年3月，Weisberg女士在WW International，Inc.（前身为Weight Watchers International，Inc.）担任SEC报告高级经理。1998年10月至2003年11月，Weisberg女士在移动数据捕获和传输设备制造商和供应商Symbol Technologies, Inc.担任高级审计师和公司会计经理。从1992年1月至1998年10月，Weisberg女士在安永会计师事务所担任审计员。
- Kathleen Weisberg,was appointed the Company's Chief Financial Officer effective July 1, 2023. Prior to her appointment as Chief Financial Officer, Ms. Weisberg served as the Company's Corporate Controller from June 2020 to June 2023. From June 2017 to June 2020, Ms. Weisberg served as the Controller for Jungle Bob Enterprises, Inc., a reptile and aquarium product company. From December 2003 to March 2010, Ms. Weisberg served as the Senior Manager for SEC Reporting at WW International, Inc., formerly Weight Watchers International, Inc. From October 1998 to November 2003, Ms. Weisberg served as Senior Auditor and Corporate Accounting Manager for Symbol Technologies, Inc., a manufacturer and supplier of mobile data capture and delivery equipment. From January 1992 to October 1998, Ms. Weisberg was an auditor at Ernst & Young LLP.
- Terence Wise
Terence Wise自2012年2月起任董事。他是Justwise集团主席，Justwise集团他于1977年创立。除了他的商业管理技能，他还为董事会带来了在亚洲市场的丰富经验。他还担任Forward China的总监。
Terence Wise serves as principal and Chairman of The Justwise Group Limited ("Justwise") which he founded in 1977. Mr. Wise also serves as a principal and owner of Forward Industries Asia-Pacific Corporation ("Forward China"), a buying and supplier agent in the Asia-Pacific region and has significant shareholdings in two furniture manufacturing plants in China. See the section titled "Related Person Transactions" below.- Terence Wise自2012年2月起任董事。他是Justwise集团主席，Justwise集团他于1977年创立。除了他的商业管理技能，他还为董事会带来了在亚洲市场的丰富经验。他还担任Forward China的总监。
- Terence Wise serves as principal and Chairman of The Justwise Group Limited ("Justwise") which he founded in 1977. Mr. Wise also serves as a principal and owner of Forward Industries Asia-Pacific Corporation ("Forward China"), a buying and supplier agent in the Asia-Pacific region and has significant shareholdings in two furniture manufacturing plants in China. See the section titled "Related Person Transactions" below.